Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

ABT.NYSE

Abbott Laboratories

Healthcare | Medical Devices

Global healthcare company developing medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.

Flagship Insight

Why Weight Loss Drug Adoption Actually Catalyzes Next Generation Biosensor Demand

High consensus across institutional reports reveals that metabolic monitoring technology is crossing an inflection point from medical necessity to consumer longevity tech. While near-term integration costs and currency headwinds present minor friction, the underlying cash flow engine and expanding biosensor market provide robust long-term defensive compounding.

Forecast TimelineUpdated On Jul 02 2026

Abbott Laboratories (ABT) Stock Forecast and AI Rating

Recommendation

No Action - Keep Monitoring

Only one horizon is positive; wait for broader confirmation.

2027

1-Year

NEUTRAL

$106

+11.3%

2029

3-Year

N/A

$127

+28%

2031

5-Year

BUY

$147

+54%

+58% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The core investment thesis centers on the structural transition of metabolic monitoring from a niche diabetes utility to a ubiquitous consumer health telemetry platform. Despite near-term integration friction from recent oncology diagnostics acquisitions and regulatory compliance adjustments, the asset represents a highly resilient cash-flow compounding engine. In a macroeconomic regime characterized by restrictive monetary policy, elevated capital costs, and geopolitical supply-chain fragmentation, the company's self-funding capacity and minimal leverage provide a significant competitive advantage, positioning it to consolidate market share from capital-starved competitors. This defensive profile is further enhanced by deep regulatory capture and long-term demographic tailwinds.

Key insights

Secular expansion of the continuous glucose monitoring market driven by behavioral synergies with weight-loss therapies.
Strategic entry into the precision oncology screening market via high-growth diagnostic acquisitions, expanding the total addressable market.
Pristine balance sheet with minimal leverage insulating the enterprise from refinancing risks and credit cycle contractions.
Geopolitical supply-chain decoupling and domestic manufacturing alignment providing a structural regulatory moat against foreign competitors.
Near-term margin compression from packaging cost inflation, logistics bottlenecks, and foreign exchange translation headwinds.
Potential long-tail civil litigation liabilities requiring structured financial reserves but not threatening long-term solvency.
High switching costs in hospital diagnostics systems securing predictable, recurring revenue streams over a multi-year horizon.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Abbott Laboratories quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Abbott Laboratories.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$91.58	$96.99	$100.17	$736.09
Quarter 2+6M	Jan 02, 2027	$88.84	$98.87	$105.17	$724.14
Quarter 3+9M	Apr 02, 2027	$84.39	$100.93	$110.43	$713.57
Quarter 4+1Y	Jul 02, 2027	$89.46	$104.34	$113.74	$723.38
Quarter 5+15M	Oct 02, 2027	$87.67	$106.16	$118.29	$716.61
Quarter 6+18M	Jan 02, 2028	$89.42	$109.19	$123.02	$738.34
Quarter 7+21M	Apr 02, 2028	$92.11	$111.93	$126.71	$746.91
Quarter 8+2Y	Jul 02, 2028	$95.79	$113.96	$129.25	$771.93
Quarter 9+27M	Oct 02, 2028	$97.71	$116.64	$133.12	$782.73
Quarter 10+30M	Jan 02, 2029	$102.59	$118.57	$135.79	$807.31
Quarter 11+33M	Apr 02, 2029	$104.64	$121.69	$139.86	$822.72
Quarter 12+3Y	Jul 02, 2029	$107.78	$125.01	$142.66	$846.10
Quarter 13+39M	Oct 02, 2029	$106.70	$127.20	$146.94	$852.53
Quarter 14+42M	Jan 02, 2030	$103.50	$129.74	$149.96	$882.91
Quarter 15+45M	Apr 02, 2030	$107.64	$132.62	$152.96	$900.46
Quarter 16+4Y	Jul 02, 2030	$109.80	$135.18	$158.60	$922.67
Quarter 17+51M	Oct 02, 2030	$107.60	$137.20	$161.77	$935.91
Quarter 18+54M	Jan 02, 2031	$110.83	$140.63	$166.62	$952.30
Quarter 19+57M	Apr 02, 2031	$113.04	$143.79	$171.62	$976.28
Quarter 20+5Y	Jul 02, 2031	$114.17	$146.71	$175.05	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The variant perception lies in a fundamental misunderstanding of metabolic biology and corporate economics. While the crowd fears that weight-loss drugs will destroy the continuous glucose monitoring market, clinical reality demonstrates that patients on these intensive therapies actually require more continuous monitoring to manage metabolic adaptation, track muscle loss, and prevent hypoglycemia. Furthermore, the market is over-indexing on the short-term earnings dilution of the recent diagnostics acquisition, failing to recognize that integrating these assets creates a global oncology diagnostics monopoly at the S-curve inflection point for liquid biopsies. Finally, the company's pristine balance sheet and massive free cash flow are severely undervalued in a high-interest-rate environment, where they function as a predatory weapon for market consolidation rather than just a defensive safety net.

Advisor Disagreement

The primary disagreement across reports centers on the near-term financial impact and strategic wisdom of the recent multi-billion-dollar diagnostics acquisition. Some perspectives view the transaction as a dilutive capital allocation error that elevates debt levels and compresses near-term margins during a restrictive rate cycle. Conversely, other views interpret the acquisition as a highly accretive, long-term masterstroke that secures a dominant oncology diagnostic monopoly. Additionally, there is minor divergence regarding the severity of the infant formula litigation, with some modeling catastrophic multi-billion-dollar liabilities and others assuming a manageable, ring-fenced civil settlement.

Financial Reviews by iPulse AI

Earnings and financials

The reports agree that the company's overall financial health is incredibly strong, highlighted by steady revenue growth and a massive annual free cash flow of over seven billion dollars. This cash generation acts as a powerful shield during tough economic times. However, there is a clear disagreement regarding near-term earnings quality. Some reports point out that recent net income has dropped due to legal costs and the expenses of buying a major cancer-screening business, which could temporarily hurt earnings per share. Other reports look past this short-term noise, emphasizing that the core medical device and biosensor divisions are growing rapidly. Ultimately, while some see temporary financial speed bumps from the acquisition, all agree that the company's long-term ability to generate cash remains intact, making it a highly reliable compounder for patient investors.

Profitability and margins

The company maintains highly impressive profitability, with gross margins consistently holding strong at around fifty-six percent. This high level of profitability is driven by the steady, recurring sales of its popular medical devices and diagnostic tests. However, the reports highlight a near-term clash regarding operating margins. Some reports point out that operating margins have recently faced downward pressure due to the integration costs of the new cancer-screening business and rising costs for packaging materials caused by global shipping disruptions. Other reports remain highly optimistic, arguing that these margin pressures are only temporary. They believe that as the company integrates its new high-margin diagnostics and scales up its glucose monitoring business, overall profitability will expand significantly over the next few years. Ultimately, while near-term margins may look slightly messy due to acquisition costs, the company's long-term pricing power and ability to pass costs to customers remain highly secure.

Balance sheet and leverage

The consensus across all reports is that the company's balance sheet is an absolute fortress, offering incredible safety and financial firepower. With a very low debt-to-equity ratio of 0.29 and interest coverage showing that the company can easily pay its debt obligations many times over, there is virtually zero risk of financial distress. This financial strength is a massive advantage in today's high-interest-rate environment, allowing the company to fund its operations, pay steady dividends, and buy back stock without needing expensive bank loans. The only point of minor disagreement is how the recent multi-billion-dollar debt issuance to fund its latest acquisition affects this safety. Some reports note that the new debt slightly reduces the company's immediate cash buffer and limits short-term flexibility. However, all agree that the company's massive cash flow easily covers these new obligations, keeping its overall financial safety fully intact.

Capex and investment intensity

The company maintains a highly disciplined approach to capital spending, typically keeping capital expenditures around five percent of its total revenue. The reports agree that this low spending intensity is a major advantage, as the company does not need to constantly reinvest massive amounts of cash just to maintain its market position. Instead, its heavy spending is focused on strategic, long-term growth, such as automating manufacturing lines for its popular glucose sensors and expanding domestic production to comply with new biosecurity laws. The main area of disagreement is whether the recent multi-billion-dollar acquisition represents a smart use of capital or an expensive distraction. While some view it as a vital move to buy next-generation cancer-screening technology, others worry it will temporarily lower the company's return on investment. Overall, the company's ability to self-fund its growth protects it from high interest rates.